Samyang Biopharm USA
Developer and manufacturer of bioabsorbable medical devices, pharmaceuticals and gene-therapeutic delivery technologies. Core activities include synthesis and processing of biodegradable polymers for surgical sutures and implantable devices, development of nucleic-acid delivery platforms, and contract development and manufacturing services for injectable drugs. Operates R&D and production sites in Korea and a production facility in Hungary, and pursues Open Innovation partnerships for gene therapeutics.
Industries
N/A
Nr. of Employees
small (1-50)
Samyang Biopharm USA
Samyang Discovery Center, 295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 13488
Products
Absorbable surgical sutures and suture materials
Range of multifilament and monofilament synthetic absorbable sutures produced from bioabsorbable polyesters with varied absorption profiles and tensile strengths for general and minimally invasive surgery.
Hemostatic and anti-adhesion surgical materials
Products based on oxidized regenerated cellulose and other biodegradable formulations designed for local hemostasis and prevention of post-surgical adhesion.
Injectable aesthetic fillers and microsphere products
Injectable fillers combining polycaprolactone-based biodegradable microspheres with water-soluble carriers and porous polymeric microspheres engineered for wrinkle improvement and aesthetic indications.
Polymeric raw materials for medical use
Production of biodegradable polymer raw materials (glycolide, lactide, p-dioxanone) used as feedstock for sutures, drug delivery agents and orthopedic devices.
Absorbable surgical sutures and suture materials
Range of multifilament and monofilament synthetic absorbable sutures produced from bioabsorbable polyesters with varied absorption profiles and tensile strengths for general and minimally invasive surgery.
Hemostatic and anti-adhesion surgical materials
Products based on oxidized regenerated cellulose and other biodegradable formulations designed for local hemostasis and prevention of post-surgical adhesion.
Injectable aesthetic fillers and microsphere products
Injectable fillers combining polycaprolactone-based biodegradable microspheres with water-soluble carriers and porous polymeric microspheres engineered for wrinkle improvement and aesthetic indications.
Polymeric raw materials for medical use
Production of biodegradable polymer raw materials (glycolide, lactide, p-dioxanone) used as feedstock for sutures, drug delivery agents and orthopedic devices.
Services
Contract development and manufacturing covering dosage form development, test method development, safety testing, commercial production and quality assurance for lyophilized and liquid injectables.
Collaborative models including joint/sponsored research, licensing, investment and joint ventures to advance nucleic-acid-based vaccines and gene therapies using tissue-selective delivery platforms.
Contract development and manufacturing covering dosage form development, test method development, safety testing, commercial production and quality assurance for lyophilized and liquid injectables.
Collaborative models including joint/sponsored research, licensing, investment and joint ventures to advance nucleic-acid-based vaccines and gene therapies using tissue-selective delivery platforms.
Expertise Areas
- Biodegradable polymer synthesis and processing
- Surgical suture manufacturing and finishing
- Biosurgery materials and hemostatic/anti-adhesion products
- Medical aesthetics device development
Key Technologies
- Aliphatic biodegradable polyesters (PGA, PLA, PCL, PLGA)
- Oxidized regenerated cellulose (ORC) formulation
- Porous polymeric microsphere fabrication
- Self-assembled amphiphilic polymer hydrogels
News & Updates
Established a synthetic biodegradable suture production plant in Hungary (Gödöllő Industrial Park) to expand European supply; facility completed in 2022.
Biodegradable suture recognized as a world-class product in 2019.
Finished suture product received U.S. FDA approval (1999) and CE marking (2002); company maintains multiple ISO and GMP certifications.
Established a synthetic biodegradable suture production plant in Hungary (Gödöllő Industrial Park) to expand European supply; facility completed in 2022.
Biodegradable suture recognized as a world-class product in 2019.
Finished suture product received U.S. FDA approval (1999) and CE marking (2002); company maintains multiple ISO and GMP certifications.